Genscript Biotech Corporation (FRA:G51)

Genscript Biotech Statistics

Total Valuation

FRA:G51 has a market cap or net worth of EUR 3.67 billion. The enterprise value is 3.34 billion.

Market Cap	3.67B
Enterprise Value	3.34B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	2.19B
Shares Outstanding	n/a
Shares Change (YoY)	+4.08%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.22%
Owned by Institutions (%)	15.37%
Float	1.38B

Valuation Ratios

The trailing PE ratio is 1.39 and the forward PE ratio is 39.89.

PE Ratio	1.39
Forward PE	39.89
PS Ratio	5.21
PB Ratio	0.98
P/TBV Ratio	0.98
P/FCF Ratio	33.59
P/OCF Ratio	18.88
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 207.92, with an EV/FCF ratio of 30.54.

EV / Earnings	1.26
EV / Sales	4.65
EV / EBITDA	207.92
EV / EBIT	n/a
EV / FCF	30.54

Financial Position

The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.12.

Current Ratio	1.96
Quick Ratio	1.78
Debt / Equity	0.12
Debt / EBITDA	2.20
Debt / FCF	4.27
Interest Coverage	12.85

Financial Efficiency

Return on equity (ROE) is -1.94% and return on invested capital (ROIC) is 2.88%.

Return on Equity (ROE)	-1.94%
Return on Assets (ROA)	2.56%
Return on Invested Capital (ROIC)	2.88%
Return on Capital Employed (ROCE)	3.71%
Revenue Per Employee	122,227
Profits Per Employee	459,259
Employee Count	5,568
Asset Turnover	0.19
Inventory Turnover	8.23

Taxes

In the past 12 months, FRA:G51 has paid 14.98 million in taxes.

Income Tax	14.98M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +22.44% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+22.44%
50-Day Moving Average	1.77
200-Day Moving Average	1.62
Relative Strength Index (RSI)	40.55
Average Volume (20 Days)	15

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:G51 had revenue of EUR 705.13 million and earned 2.65 billion in profits. Earnings per share was 1.20.

Revenue	705.13M
Gross Profit	391.05M
Operating Income	152.78M
Pretax Income	-36.61M
Net Income	2.65B
EBITDA	201.96M
EBIT	152.78M
Earnings Per Share (EPS)	1.20

Balance Sheet

The company has 799.01 million in cash and 467.06 million in debt, giving a net cash position of 331.95 million.

Cash & Cash Equivalents	799.01M
Total Debt	467.06M
Net Cash	331.95M
Net Cash Per Share	n/a
Equity (Book Value)	3.76B
Book Value Per Share	1.73
Working Capital	490.70M

Cash Flow

In the last 12 months, operating cash flow was 194.49 million and capital expenditures -85.18 million, giving a free cash flow of 109.31 million.

Operating Cash Flow	194.49M
Capital Expenditures	-85.18M
Free Cash Flow	109.31M
FCF Per Share	n/a

Margins

Gross margin is 55.46%, with operating and profit margins of 21.67% and 375.74%.

Gross Margin	55.46%
Operating Margin	21.67%
Pretax Margin	-5.19%
Profit Margin	375.74%
EBITDA Margin	28.64%
EBIT Margin	21.67%
FCF Margin	15.50%

Dividends & Yields

FRA:G51 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.08%
Shareholder Yield	-4.08%
Earnings Yield	72.16%
FCF Yield	2.98%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:G51 has an Altman Z-Score of 2.91 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.91
Piotroski F-Score	6